In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Relaxin and Related Peptides (1)

Edited by Edited by Gillian D. Bryant-Greenwood (University of Hawaii John A. Burns School of Medicine), Carol A. Bagnell (Rutgers University), and Ross A.D. Bathgate (University of Melbourne)
Relaxin and Related Peptides (1)

Published: April 2009

Volume 1160

Learn More

Relaxin is a peptide hormone belonging to the insulin superfamily of hormones. Originally identified as the factor responsible for the widening of the pubic ligament in preparation for birth, relaxin was primarily considered to be a reproductive hormone. In recent years, however, the actions of relaxin and the number of relaxin-like members of this hormone family have increased; for example four relaxin-like hormones have now been discovered. Relaxin is now considered to be a cardiovascular hormone. It is produced and functions in the heart and blood vessels, has important anti-fibrotic actions in the kidney and lung,and is involved in tumor development via its angiogenic actions. Agonists and antagonists to relaxins and receptors are currently being developed and will likely have important clinical implications.